Ventris Medical Earns FDA Clearance for its New Connext Surgical Matrix

The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Ventris Medical for its advanced Connext Surgical Matrix, a precisely engineered collagen wound dressing designed to improve wound healing and help mitigate common complications.

The product aims to optimize patient recovery by comprehensively supporting the wound-healing cascade, thereby reducing the incidence of infection, seromas, hematomas, and drainage after surgical procedures.

“The introduction of our new Connext Surgical Matrix is a direct response to critical unmet needs within the medical community,” Ventris Medical CEO Russell Cook said. “Connext offers a significant leap forward in patient care by intentionally targeting the biology of the surgical wound environment, which supports normal healing processes. The new design is intended to minimize common postoperative complications such as infection, seromas, hematomas, and drainage.”

The Ventris Medical Connext Surgical Matrix distinguishes itself through a combination of advanced material science and application innovation. Sourced from bovine Achilles tendon, the highly purified Type 1 collagen used in the Connext Surgical Matrix leverages robust biological properties known to support tissue regeneration and repair. This collagen source directly contributes to the natural healing processes within the wound bed, fostering an optimal environment for normal re-epithelialization. 

Its advanced processing and formulation features a uniform particle size, a carefully maintained pH, and low endotoxin levels, all crucial attributes that make it amenable for use in any spinal fusion procedure, according to the company. The particle size and low pH allows rapid, uniform absorption of wound exudates, while the low endotoxin level ensures its suitability and safety for use in highly sensitive surgical environments. This meticulous design can minimize inflammatory responses, paving the way for more predictable and enduring healing outcomes.

Furthermore, its easy application is facilitated by a proprietary bellow spray system, allowing for precise and consistent deployment across even the most challenging wound bed anatomies. This streamlined delivery method is designed to optimize surgical workflow, ensuring uniform coverage and maximizing the therapeutic potential of the Matrix for comprehensive wound support and complication management.

Ventris Medical offers various allograft, synthetic, and bioactive products for soft and hard tissue applications. The company designs, develops, and markets best-in-class products for optimal surgical outcomes. Its line of human allograft products is regulated by the FDA Center for Biologics Evaluation and Research (CBER), which regulates human cells, tissues, and cellular and tissue-based products (HCT/Ps). Ventris Medical adheres to Current Good Tissue Practices, focusing extensively on donor eligibility and the recovery process. The firm’s allograft products are regulated under 21 CFR Part 1270 and 21 CFR Part 1271 and Section 361 of the Public Health Services Act.